Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Massive kidney trial aims to revolutionize how we test treatments

NCT ID NCT07595952

First seen May 26, 2026 · Last updated Jun 22, 2026 · Updated 3 times

Summary

APT-KIDNEY is a large, flexible clinical trial platform designed to test multiple treatments for advanced kidney disease more efficiently. It will enroll up to 5,000 adults with severe kidney problems or those on dialysis. By using electronic health records and adaptive methods, the platform aims to produce faster, more practical evidence to improve care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this platform could speed up testing of many kidney disease treatments, leading to faster, more reliable answers about what works.

What could go wrong

This is a trial framework, not a single treatment test. It hasn't started recruiting yet, and its success depends on many future domain-specific trials.

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.